Our mission is to offer a Type-1 inflammation therapy to solid-tumor bearing patients to help them regress and eliminate their tumors.
We aim to ease the pain inflicted by cancer with an efficient therapy to free cancer patients of their tumors and to reduce the cost and strain of cancer treatment.
We believe that the best cancer treatment that can be developed is one that can reproduce the natural mechanism that the human body uses to eliminate tumors.
Current cancer therapies such as surgery, chemotherapy and radiotherapy are not so efficient to eliminate cancer from patients bearing solid tumors. On average, 43% of cancer patients die within 5 years. Some cancers such as lung tumors have a survival rate of only 14%. When common cancers such as breast or colon tumors are diagnosed at advance stage, the five year survival rate drop to 26 and 10% respectively. One problem is that current treatment regimens weaken patient's anticancer immune defense and offer no protection against relapses. There is a crucial need to bring to patients novel cancer therapy that can offer better efficacy and protect against relapses.
